WO2023122355A3 - Methods of treating or preventing infusion-related reactions - Google Patents

Methods of treating or preventing infusion-related reactions Download PDF

Info

Publication number
WO2023122355A3
WO2023122355A3 PCT/US2022/054033 US2022054033W WO2023122355A3 WO 2023122355 A3 WO2023122355 A3 WO 2023122355A3 US 2022054033 W US2022054033 W US 2022054033W WO 2023122355 A3 WO2023122355 A3 WO 2023122355A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
methods
infusion
related reactions
preventing infusion
Prior art date
Application number
PCT/US2022/054033
Other languages
French (fr)
Other versions
WO2023122355A2 (en
Inventor
Barry Jay KAPPEL
Gene Merutka
Jimmy Andrew ROTOLO
Alice Susannah BEXON
Robert E. MICHAEL
Original Assignee
Sapience Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapience Therapeutics, Inc. filed Critical Sapience Therapeutics, Inc.
Publication of WO2023122355A2 publication Critical patent/WO2023122355A2/en
Publication of WO2023122355A3 publication Critical patent/WO2023122355A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Abstract

Provided are methods of treating or preventing an infusion-related reaction (IRR) in a subject receiving an intravenous infusion of a pharmaceutical composition, the method comprising administering a leukotriene inhibitor to the subject before and/or during infusion.
PCT/US2022/054033 2021-12-24 2022-12-26 Methods of treating or preventing infusion-related reactions WO2023122355A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163293706P 2021-12-24 2021-12-24
US63/293,706 2021-12-24

Publications (2)

Publication Number Publication Date
WO2023122355A2 WO2023122355A2 (en) 2023-06-29
WO2023122355A3 true WO2023122355A3 (en) 2023-08-31

Family

ID=86903728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/054033 WO2023122355A2 (en) 2021-12-24 2022-12-26 Methods of treating or preventing infusion-related reactions

Country Status (1)

Country Link
WO (1) WO2023122355A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140235557A1 (en) * 2011-06-20 2014-08-21 Commissariat A L'energie Atomique Et Aux Energies Alternatives Small Efficient Cell Penetrating Peptides Derived From The Scorpion Toxin Maurocalcine
US20170172979A1 (en) * 2014-02-19 2017-06-22 Yeda Research And Development Co. Ltd. Inhibitors of leukotriene-mediated activity for treating side effects of statin therapy
WO2020240434A1 (en) * 2019-05-28 2020-12-03 Janssen Biotech, Inc. Method of providing safe administration of an anti-cd40 antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140235557A1 (en) * 2011-06-20 2014-08-21 Commissariat A L'energie Atomique Et Aux Energies Alternatives Small Efficient Cell Penetrating Peptides Derived From The Scorpion Toxin Maurocalcine
US20170172979A1 (en) * 2014-02-19 2017-06-22 Yeda Research And Development Co. Ltd. Inhibitors of leukotriene-mediated activity for treating side effects of statin therapy
WO2020240434A1 (en) * 2019-05-28 2020-12-03 Janssen Biotech, Inc. Method of providing safe administration of an anti-cd40 antibody

Also Published As

Publication number Publication date
WO2023122355A2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2003020024A3 (en) Treatment and prevention of infections in plants
WO2003097111A3 (en) System and method for permitting sterile operation of a sedation and analgesia system
WO2003082212A3 (en) Method for treating cancer in humans
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
WO2004091539A3 (en) Fluid mixing methods and apparatus
CA2567517A1 (en) System, method, and computer program product for handling, mixing, dispensing, and injecting radiopharmaceutical agents
WO2007029008A3 (en) Method of treatment or prevention of age-related macular degeneration
WO2002056937A3 (en) Devices, systems and methods for acute or chronic delivery of substances or apparatus to extravascular treatment sites
WO2003037060A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2003096977A3 (en) Methods of treating hepatitis
AU1416795A (en) Paramunity inducer based on combinations of poxvirus components, process to prepare it and its use as medicament
NO20066054L (en) treatment with cisplatin and an EGFR inhibitor
GEP20043285B (en) Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
WO2015106295A3 (en) Enolase 1 (eno1) compositions and uses thereof
WO2023122355A3 (en) Methods of treating or preventing infusion-related reactions
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
TW200510437A (en) Phosphinane compound with immunomodulating activity
WO2019152343A8 (en) Methods of desensitizing against infusion associated reactions in lysosomal acid lipase deficiency (lal-d) patients treated with exogenous lysosomal acid lipase (lal)
WO2020247819A3 (en) Methods of treatment with aminolevulinic acid synthase 2 (alas2) modulators
WO1988007367A3 (en) Melatonin-derivatives for psychogenic stress and acute anxiety, and immuno-stimulant drugs
Corso et al. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma
Mendizabal Bugs
WO2021074897A3 (en) Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
CN114452403A8 (en) Pharmaceutical composition containing bifunctional immune checkpoint/TGF (transforming growth factor beta) inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22912539

Country of ref document: EP

Kind code of ref document: A2